Cutaneous melanoma

Alexander M.M. Eggermont(University Medical Center Utrecht), Caroline Robert(Institut Gustave Roussy), Alan Spatz(Jewish General Hospital)
The Lancet
September 18, 2013
10.1016/s0140-6736(13)60802-8
Cited by 533

Related Papers

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k